文献速递心外重症与机械循环支持

儿童心室辅助装置的可调控危险因素减少及移植时持续可调控危险因素的影响

Modifiable risk factor reduction for pediatric ventricular assist devices and the influence of persistent modifiable risk factors at transplant.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-07-05

本研究回顾性分析本机构2011至2022年移植时需心室辅助装置(VAD)的39例患儿,发现VAD植入时18例有≥3个可调控危险因素(MRF),移植时降至6例;移植时≥3个MRF者医院死亡率为50%(3/6),显著高于1至2个和0个MRF者的0%(P=.01)。结论认为VAD与MRF减少相关,但移植时持续MRF者死亡负担高,移植≥3个MRF的VAD患者可能并不明智,应给予VAD支持时间以实现移植前积极优化。

要点

  • VAD植入时18例有≥3个MRF,移植时降至6例,16例无MRF。
  • 移植时≥3个MRF者医院死亡率为50%(3/6),1至2个和0个MRF者为0%(P=.01)。
  • 移植时≥3个MRF者总体移植后生存较0个MRF者显著更差(P=.006)。

核心结论

  • VAD与儿童MRF减少相关,但移植时持续MRF者死亡负担高。
  • 移植≥3个MRF的VAD患者可能并不明智。
  • 应给予VAD支持时间以实现移植前积极优化MRF。

研究设计与样本

  • 回顾性识别本机构2011至2022年移植时需要VAD的所有患者,共39例。
  • MRF包括肾功能不全(估算肾小球滤过率<60 mL/min/1.73 m2)、肝功能障碍(总胆红素≥1.2 mg/dL)、全肠外营养依赖、镇静剂、肌松剂、正性肌力药和机械通气。

主要发现

  • VAD植入时18例有≥3个MRF,21例有1至2个MRF,0例无MRF。
  • 移植时6例有≥3个MRF,17例有1至2个MRF,16例无MRF。
  • 医院死亡率在移植时≥3个MRF者为50%(3/6),1至2个和0个MRF者为0%(P=.01,≥3 vs 1-2和0)。
  • 与医院死亡独立相关的MRF包括肌松剂(1.76 [范围,1.32-2.30])、呼吸机(1.59 [范围,1.28-1.97])、全肠外营养依赖(1.49 [范围,1.07-2.07])和肾功能不全(1.31 [范围,1.02-1.67])。
  • 发生两例晚期死亡(3.6年和5.7年),均为移植时有1至2个MRF者;总体移植后生存≥3个MRF者较0个MRF者显著更差(P=.006),其他队列间相当(P>.1)。

临床怎么用

  • 作者认为移植≥3个MRF的VAD患者可能并不明智。
  • 作者建议应给予VAD支持时间以实现移植前积极优化MRF。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Ventricular assist devices (VADs) are associated with a mortality benefit in children. Database-driven analyses have associated VADs with reduction of modifiable risk factors (MRFs), but validation with institutional data is required. The authors studied MRF reduction on VAD and the influence of persistent MRFs on survival after heart transplant. METHODS: All patients at the authors' institution requiring a VAD at transplant (2011-2022) were retrospectively identified. MRFs included renal dysfunction (estimated glomerular filtration rate <60 mL/min/1.73 m2), hepatic dysfunction (total bilirubin ≥1.2 mg/dL), total parenteral nutrition dependence, sedatives, paralytics, inotropes, and mechanical ventilation. RESULTS: Thirty-nine patients were identified. At time of VAD implantation, 18 patients had ≥3 MRFs, 21 had 1 to 2 MRFs, and 0 had 0 MRFs. At time of transplant, 6 patients had ≥3 MRFs, 17 had 1 to 2 MRFs, and 16 had 0 MRFs. Hospital mortality occurred in 50% (3 out of 6) patients with ≥3 MRFs at transplant vs 0% of patients with 1 to 2 and 0 MRFs (P = .01 for ≥3 vs 1-2 and 0 MRFs). MRFs independently associated with hospital mortality included paralytics (1.76 [range, 1.32-2.30]), ventilator (1.59 [range, 1.28-1.97]), total parenteral nutrition dependence (1.49 [range, 1.07-2.07]), and renal dysfunction (1.31 [range, 1.02-1.67]). Two late mortalities occurred (3.6 and 5.7 y), both in patients with 1 to 2 MRFs at transplant. Overall posttransplant survival was significantly worse for ≥3 versus 0 MRFs (P = .006) but comparable between other cohorts (P > .1). CONCLUSIONS: VADs are associated with MRF reduction in children, yet those with persistent MRFs at transplant experience a high burden of mortality. Transplanting VAD patients with ≥3 MRFs may not be prudent. Time should be given on VAD support to achieve aggressive pre-transplant optimization of MRFs.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Greenberg JW, Kulshrestha K, Guzman-Gomez A, et al. Modifiable risk factor reduction for pediatric ventricular assist devices and the influence of persistent modifiable risk factors at transplant. J Thorac Cardiovasc Surg. 2023. PMID: 37414356. doi:10.1016/j.jtcvs.2023.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。